WP 1303

Drug Profile

WP 1303

Alternative Names: H-1129; WP-1303

Latest Information Update: 28 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator D. Western Therapeutics Institute
  • Developer D. Western Therapeutics Institute; Wakamoto
  • Class Antiglaucomas; Quinolines; Small molecules; Sulfonamides
  • Mechanism of Action HSP90 heat-shock protein inhibitors; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glaucoma; Ocular hypertension

Most Recent Events

  • 15 Mar 2017 D.Western Therapeutics Institute completes a phase I trial in Glaucoma and Ocular hypertension (In volunteers) in Japan
  • 02 Feb 2017 D. Western Therapeutics plans a phase II trial for Glaucoma in Japan in 2017
  • 02 Feb 2017 D. Western Therapeutics plans a phase III trial for Glaucoma in Japan in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top